^
Association details:
| Biomarker: | HIF1A overexpression |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
21P-BACH1 and HIF1a predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC)
Published date:
05/03/2021
Excerpt:
Overall, BACH1 and HIF1α continuous expressions were significantly associated with increased pCR (OR=4.21 [95%CI 1.44-12.30), p=0.009), OR=2.08 [95%CI 1.14-3.82], p=0.018, respectively)…HER2-negative BC with elevated BACH1 and HIF1α expression benefits from nP-based treatment. There was a positive correlation between increased BACH1 and HIF1α levels for predicting pCR.
Trial ID:
